Skip to main content

Table 1 Baseline Characteristics of Patients with HCAP and CAPa

From: Healthcare-associated pneumonia among hospitalized patients in a Korean tertiary hospital

Baseline Characteristics

HCAP (n = 231)

CAP

(n = 296)

P- value

Age (year)

63.5 ± 13.1

65.4 ± 15.7

0.148

Male

162 (70.1)

194 (65.5)

0.264

Female

69 (29.9)

102 (34.5)

 

Underlying diseases

   

   Diabetes Mellitus

52 (22.5)

59 (19.9)

0.471

   Chronic lung diseaseb

22 (9.5)

56 (18.9)

0.003

   Central nervous system disorders

26 (11.3)

47 (15.9)

0.127

   Renal disease

31 (13.4)

27 (9.1)

0.118

   Hypertension

93 (40.3)

125 (42.2)

0.649

   Cardiovascular disease

19 (8.2)

62 (20.9)

<0.001

   Liver disease

12 (5.2)

16 (5.4)

0.915

   Rheumatologic disease

9 (3.9)

18 (6.1)

0.259

   Malignancy

156 (67.5)

58 (19.6)

<0.001

Solid organ malignancy

133 (57.6)

42 (14.2)

<0.001

Hematologic malignancy

26 (11.3)

17 (5.7)

0.022

Clinical parameters

   

   Confusion

35 (15.2)

34 (11.5)

0.216

   Septic shock at onset

57 (24.7)

46 (15.5)

0.009

   PaO2 < 60 mmHg, SpO2 < 90%, or PaO2/FiO2 < 300

79 (34.2)

96 (32.4)

0.669

   Pleural effusion

43 (18.6)

49 (16.6)

0.536

   Acute renal failure at onset

32 (13.9)

37 (12.5)

0.648

Laboratory findings

   

   pH < 7.35

10 (4.3)

23 (7.8)

0.106

   Hematocrit < 30%

87 (37.7)

51 (17.2)

<0.001

   Glucose > 250 mg/dL

20 (8.7)

21 (7.1)

0.506

   Blood urea nitrogen > 30 mg/dL

67 (29.0)

49 (16.6)

0.001

   Leukocytes (×103/μl)

12790 ± 13603

13175 ± 7519

0.700

   C-reactive protein (mg/dL)

15.4 ± 11.2

13.1 ± 10.0

0.017

   Erythrocyte Sedimentation Rate (mm)

83.2 ± 33.8

71.4 ± 35.7

<0.001

Eastern Cooperative Oncology

Group (ECOG)

1.7 ± 0.9

1.2 ± 0.9

<0.001

Prior antibiotics use

97 (42.0)

6 (1.0)

<0.001

Immunosuppressedc

142 (61.5)

39 (13.2)

<0.001

Pneumonia Severity Index Risk Classes

113.7 ± 32.3

92.2 ± 33.6

<0.001

   Low (I-III)

55 (23.8)

159 (53.7)

 

   Intermediate (IV)

115 (49.8)

99 (33.4)

<0.001

   High (V)

61 (26.4)

38 (12.8)

 
  1. a Data are presented as numbers (percentages) unless otherwise indicated. Plus-minus values are means ± standard deviation.
  2. b Chronic lung disease includes asthma, COPD, and structural lung diseases, such as bronchiectasis and interstitial lung disease
  3. c Immunosuppression includes the following: (1) daily administration of systemic corticosteroids (at least 15 mg of prednisone per day for more than one month or combination therapy with low dose corticosteroids and other immunosuppressants including azathioprine, mycophenolate, methotrexate, cyclosporine, or cyclophosphamide); (2) seropositivity for human immunodeficiency virus; (3) received either a solid organ transplant or bone marrow transplant; (4) treated with radiation therapy or chemotherapy for an underlying malignancy during the 6 months prior to hospital admission; (5) an underlying acquired immune deficiency disorder
  4. HCAP healthcare-associated pneumonia
  5. CAP community-acquired pneumonia
Back to article page

BMC Infectious Diseases

ISSN: 1471-2334

Contact us